News
US Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether a gene therapy from ...
A panel selected by FDA Commissioner Marty Makary, MD, MPH, unanimously urged the agency to remove the boxed warning on ...
Dr. Marty Makary, the agency’s commissioner, said too many women avoid hormone therapy because the risks have been overstated ...
4h
Asianet Newsable on MSNFDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The MarketThe growing number of fatalities is raising questions about the future of Sarepta’s therapies and the regulatory path for ...
The Food and Drug Administration plans to ask Sarepta Therapeutics Inc. to pause shipments of its Elevidys treatment after ...
19h
News Nation on MSNFDA chief: HRT warning among ‘greatest mistakes of modern medicine’( NewsNation) — The head of the U.S. Food and Drug Administration signaled Thursday that he supports changing or removing the ...
Explore more
Sarepta Therapeutics (NASDAQ:SRPT) shares dropped to a new 52-week low on Friday, triggering a trading halt after Bloomberg ...
The U.S. Food and Drug Administration is planning to request Sarepta Therapeutics to voluntarily stop all shipments of its ...
23h
AFP on MSNUS may revise hormone replacement therapy warningsUS Food and Drug Administration Commissioner Marty Makary signaled Thursday that he is open to revising strict warning labels ...
Shares of Sarepta Therapeutics plunged more than 30% on Friday as the future of its approved gene therapy appeared at risk.
“Now, by expanding the palette of available colors derived from natural sources, food manufacturers have a variety of options ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results